BIOA

In January 2026, BioAge Labs completed an upsized public offering, generating approximately $132.3 million. Positive interim Phase 1 data for BGE-102, showing strong reductions in inflammatory biomarkers, was announced in December 2025 and January 2026. Phase 2 trials for BGE-102 were initiated in June 2026 for high-risk adults with obesity and elevated inflammation (QUELL-CV) and in September 2026 for diabetic macular edema (QUELL-DME). On July 31, 2026, BioAge Labs' stock plummeted by nearly 60% after Novo Nordisk announced the failure of its Phase 3 ZEUS trial for a competitor's IL-6 pathway inhibitor, casting doubt on the broader cardiovascular inflammation hypothesis relevant to BGE-102. Over the past 52 weeks, BIOA stock has traded between a high of $25.96 and a low of $4.90, with the share price at $8.49 on September 11, 2026, representing a 76.88% increase over the price on September 12, 2025.